Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ABP) is a clinical-stage biopharmaceutical company focused on the development of bispecific antibody therapeutics, operating in the biotechnology and life sciences sector. The company reached public markets through a de-SPAC business combination and filed its Form 10-Q with the Securities and Exchange Commission on August 22, 2023, covering quarterly financial and operational disclosures under accession number 0001193125-23-218080. As a post-combination reporting company, Abpro Holdings is subject to standard SEC periodic reporting requirements applicable to publicly traded biotech issuers. Investors and analysts seeking complete filing history, deal structure data, and SPAC transaction analytics for ABP and hundreds of comparable issuers can sign up for full access at SpacDesk.